Parathyroid hormone type 1 receptor regulates osteosarcoma K7M2 Cell growth by interacting with angiotensinogen

This study aimed to determine the interactions between parathyroid hormone type 1 receptor (PTHR1) and angiotensinogen (AGT) and the effects of these agents on osteosarcoma (OS). We constructed a stably transfected mouse OS K7M2 cell line (shPTHR1‐ K7M2) using shRNA and knocked down AGT in these cells using siRNA‐AGT. The transfection efficiency and expression of AGT, chemokine C‐C motif receptor 3 (CCR3), and chemokine (C‐C motif) ligand 9 (CCL9) were determined using real‐time quantitative PCR. Cell viability and colony formation were assessed using Cell Counting Kit‐8 and crystal violet staining, respectively. Cell apoptosis and cycle phases were assessed by flow cytometry, and cell migration and invasion were evaluated using Transwell assays. Interference with PTHR1 upregulated the expression of AGT and CCR3, and downregulated that of CCL9, which was further downregulated by AGT knockdown. Cell viability, migration, invasion and colony formation were significantly decreased, while cell apoptosis was significantly increased in shPTHR1‐K7M2, compared with those in K7M2 cells (P < .05 for all). However, AGT knockdown further inhibited cell viability after 72 h of culture but promoted cell migration and invasion. PTHR1 interference decreased and increased the numbers of cells in the G0/G1 and G2/M phases, respectively, compared with those in K7M2 cells. Angiotensinogen knockdown increased the number of cells in the G0/G1 phase compared with that in the shPTHR1‐K7M2 cells. Therefore, PTHR1 affects cell viability, apoptosis, migration, invasion and colony formation, possibly by regulating AGT/CCL9 in OS cells.

[1]  Robin L. Jones,et al.  Future Directions in the Treatment of Osteosarcoma , 2021, Cells.

[2]  Shenglong Li,et al.  Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling. , 2020, Journal of cellular physiology.

[3]  Wen-Zhe Yin,et al.  Mangiferin suppresses human metastatic osteosarcoma cell growth by down-regulating the expression of metalloproteinases-1/2 and parathyroid hormone receptor 1 , 2020, AMB Express.

[4]  Shenglong Li,et al.  PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes. , 2019, DNA and cell biology.

[5]  Tomoyuki Watanabe,et al.  Structure and dynamics of the active human parathyroid hormone receptor-1 , 2019, Science.

[6]  V. Gaponenko,et al.  Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness , 2019, The Journal of allergy and clinical immunology.

[7]  Jianbo Jia,et al.  miR‐21 and miR‐19b delivered by hMSC‐derived EVs regulate the apoptosis and differentiation of neurons in patients with spinal cord injury , 2018, Journal of cellular physiology.

[8]  B. Uhal,et al.  Local activation of the pulmonary extravascular angiotensin system induces epithelial apoptosis and lung fibrosis. , 2018, Journal of lung, pulmonary & respiratory research.

[9]  Minghua Li,et al.  AngII induces HepG2 cells to activate epithelial-mesenchymal transition , 2018, Experimental and therapeutic medicine.

[10]  B. Zhu,et al.  Silencing of ENO1 by shRNA Inhibits the Proliferation of Gastric Cancer Cells , 2018, Technology in cancer research & treatment.

[11]  Shenglong Li,et al.  β-Alanine mediated inhibition of PTHR1suppresses the proliferation, invasion and tumorigenesis in metastatic human osteosarcoma U2OS cells. , 2018, International journal of biological macromolecules.

[12]  A. Huber,et al.  An emerging role for eotaxins in neurodegenerative disease. , 2016, Clinical immunology.

[13]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[14]  Ke Wang,et al.  Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways , 2017, Journal of Orthopaedic Surgery and Research.

[15]  Jianlin Zhou,et al.  High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma. , 2017, Molecular medicine reports.

[16]  Hongyan Lu,et al.  Overexpression of AGT promotes bronchopulmonary dysplasis via the JAK/STAT signal pathway , 2017, Oncotarget.

[17]  Jinlong Li,et al.  Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer , 2017, Journal of experimental & clinical cancer research : CR.

[18]  M. Cui,et al.  MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer. , 2017, American journal of translational research.

[19]  S. Russell,et al.  Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart , 2016, European journal of immunology.

[20]  D. Spandidos,et al.  Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review) , 2016, Oncology reports.

[21]  K. Matsuo,et al.  Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8 , 2016, Front. Cell Dev. Biol..

[22]  Min Tian,et al.  Expression and prognostic significance of CCL11/CCR3 in glioblastoma , 2016, Oncotarget.

[23]  K. Janeway,et al.  Future directions in the treatment of osteosarcoma , 2016, Current opinion in pediatrics.

[24]  K. Hunter,et al.  CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. , 2015, Cancer research.

[25]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Martin,et al.  PTHrP, its receptor, and protein kinase A activation in osteosarcoma , 2014, Molecular & cellular oncology.

[27]  A. Chalk,et al.  Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo , 2014, Oncogene.

[28]  Jilong Yang,et al.  Advances in targeted therapy for osteosarcoma. , 2014, Discovery medicine.

[29]  Zhousheng Xiao,et al.  Downregulation of PKD1 by shRNA results in defective osteogenic differentiation via cAMP/PKA pathway in human MG‐63 cells , 2012, Journal of cellular biochemistry.

[30]  James J. Lee,et al.  CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. , 2011, American Journal of Pathology.

[31]  S. Schulz,et al.  Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. , 2010, European journal of endocrinology.

[32]  P. Corvol,et al.  Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. , 2009, Cancer research.

[33]  M. Alokail,et al.  Quantitative comparison of PTH1R in breast cancer MCF7 and osteosarcoma SaOS‐2 cell lines , 2008, Cell biochemistry and function.

[34]  A. Huvos,et al.  Over‐expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma , 2007, International journal of cancer.

[35]  P. Opolon,et al.  Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  J. Egido,et al.  Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  W. Hsueh,et al.  Angiotensin II in cell growth and matrix production. , 1995, Advances in experimental medicine and biology.